AtriCure Stock Forecast, Price & News

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure or view top-rated stocks.

How has AtriCure's stock price been impacted by Coronavirus (COVID-19)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 101.5% and is now trading at $71.08.
View which stocks have been most impacted by COVID-19.

Are investors shorting AtriCure?

AtriCure saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 693,900 shares, a decrease of 26.0% from the October 31st total of 937,400 shares. Based on an average daily trading volume, of 188,700 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.6% of the shares of the stock are short sold.
View AtriCure's Short Interest.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for AtriCure.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported $2.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $2.39. The medical device company earned $70.46 million during the quarter, compared to analysts' expectations of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 11.12% and a net margin of 17.53%. During the same period in the previous year, the firm earned ($0.11) earnings per share.
View AtriCure's earnings history.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share guidance of $-1.200-$-1.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $-1.350. The company issued revenue guidance of $270 million-$275 million, compared to the consensus revenue estimate of $272.94 million.

What price target have analysts set for ATRC?

8 equities research analysts have issued 12-month target prices for AtriCure's shares. Their forecasts range from $75.00 to $120.00. On average, they expect AtriCure's share price to reach $90.50 in the next year. This suggests a possible upside of 27.3% from the stock's current price.
View analysts' price targets for AtriCure or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

• Michael H. Carrel, President, Chief Executive Officer & Director
• Douglas J. Seith, Chief Operating Officer (LinkedIn Profile)
• Angela L. Wirick, Chief Financial Officer (LinkedIn Profile)
• Vinayak Doraiswamy, Chief Scientific Officer (LinkedIn Profile)
• Salvatore Privitera, Chief Technical Officer (LinkedIn Profile)

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AtriCure's key competitors?

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Masimo (MASI).
View all of ATRC's competitors.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.95%), Alliancebernstein L.P. (6.34%), Invesco Ltd. (4.95%), Credit Suisse AG (2.48%), Macquarie Group Ltd. (2.38%) and TimesSquare Capital Management LLC (2.07%). Company insiders that own AtriCure stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Wellington Management Group LLP, TimesSquare Capital Management LLC, Emerald Advisers LLC, Morgan Stanley, Pura Vida Investments LLC, Principal Financial Group Inc., and Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin, and Vinayak Doraiswamy.
View insider buying and selling activity for AtriCure or view top insider-selling stocks.

Which institutional investors are buying AtriCure stock?

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Balyasny Asset Management LLC, Polar Capital Holdings Plc, Assenagon Asset Management S.A., CastleArk Alternatives LLC, Dimensional Fund Advisors LP, Alliancebernstein L.P., and Macquarie Group Ltd.. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $71.08.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.26 billion and generates $206.53 million in revenue each year. The medical device company earns $-48.15 million in net income (profit) each year or $0.95 on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.

When was AtriCure founded?

AtriCure was founded in 2000.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at (513) 755-4100 or via fax at 513-755-4567.